ABSTRACT
The study evaluated the safety of a modified live-virus (MLV) porcine reproductive and respiratory syndrome (PRRS) vaccine in susceptible, pregnant gilts. To simulate inadvertent exposure secondary to postvaccination shedding of PRRS-MLV, seronegative gilts (n=51) were exposed by IM vaccination at 90 days of gestation. Vaccinated and nonvaccinated, seronegative control gilts (n=25) were maintained in separate facilities. The PRRS-MLV vaccine was given in a 2mL dose on day 0. On day 7 all vaccinated gilts were PRRSV-PCR-positive for PRRSV and had responded serologically as determined by an ELISA. All control gilts remained PRRSV-PCR- and ELISA-negative throughout the study. Abortions did not occur in gilts from either group. The difference between vaccinated and control gilts in average number of piglets per litter (12.43 and 12.16, respectively), number of live births per litter (11.21 and 11.54), and mean piglet birth weight (3.22 and 3.26 lbs) were not significantly different. Piglets in the control group had significantly greater average daily gain versus piglets from vaccinated gilts (0.52 vs. 0.46 lbs, P<0.0001). Preweaning mortality was significantly greater (P=0.0023) in piglets from the vaccinated gilts (19.7% vs. 10.9%). A single gilt accounted for 18.2% of stillbirths in the vaccinated group. Air samples were borderline PRRSV-PCR-positive for PRRSV on days 29 and 32, after more than 98% of gilts had farrowed. Results demonstrated that vaccination of pregnant gilts at the time of peak fetal susceptibility was non-abortigenic and that the PRRS-MLV agent did not significantly affect reproductive outcomes. Lower ADG in piglets from vaccinated gilts may be due to PRRS-MLV viremia following transplacental or post-farrowing exposure. Air sampling results indicated that environmental contamination with PRRS-MLV shed from vaccinated gilts was minimal.
